Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/90485
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Boia, Raquel | - |
dc.contributor.author | Salinas-Navarro, Manuel | - |
dc.contributor.author | Gallego-Ortega, Alejandro | - |
dc.contributor.author | Galindo-Romero, Caridad | - |
dc.contributor.author | Aires, Inês D. | - |
dc.contributor.author | Agudo-Barriuso, Marta | - |
dc.contributor.author | Ambrósio, António Francisco | - |
dc.contributor.author | Vidal-Sanz, Manuel | - |
dc.contributor.author | Santiago, Ana Raquel | - |
dc.date.accessioned | 2020-08-03T16:09:26Z | - |
dc.date.available | 2020-08-03T16:09:26Z | - |
dc.date.issued | 2020-05-21 | - |
dc.identifier.issn | 2041-4889 | pt |
dc.identifier.uri | https://hdl.handle.net/10316/90485 | - |
dc.description.abstract | Glaucoma is a progressive chronic retinal degenerative disease and a leading cause of global irreversible blindness.This disease is characterized by optic nerve damage and retinal ganglion cell (RGC) death. The current treatmentsavailable target the lowering of intraocular pressure (IOP), the main risk factor for disease onset and development.However, in some patients, vision loss progresses despite successful IOP control, indicating that new and effectivetreatments are needed, such as those targeting the neuroprotection of RGCs. Adenosine A3receptor (A3R) activationconfers protection to RGCs following an excitotoxic stimulus. In this work, we investigated whether the activation ofA3R could also afford protection to RGCs in the laser-induced ocular hypertension (OHT) model, a well-characterizedanimal model of glaucoma. The intravitreal injection of 2-Cl-IB-MECA, a selective A3R agonist, abolished the alterationsinduced by OHT in the negative and positive components of scotopic threshold response (STR) without changing a-and b-wave amplitudes both in scotopic and photopic conditions. Moreover, the treatment of OHT eyes with the A3Ragonist promoted the survival of RGCs, attenuated the impairment in retrograde axonal transport, and improved thestructure of the optic nerve. Taking into consideration the beneficial effects afforded by 2-Cl-IB-MECA, we can envisagethat A3R activation can be considered a good therapeutic strategy to protect RGCs from glaucomatous damage. | pt |
dc.description.sponsorship | This work was supported by Foundation for Science and Technology (FCT), Portugal (Fellowships PD/BD/114115/2015 and PD/BD/127821/2016, Grant PTDC/NEU-OSD/3123/2014; Strategic Projects UID/NEU/04539/2013, UID/NEU/04539/2019 and UIDB/04539/2020; and UIDP/04539/2020 (CIBB)), FEDER-COMPETE (FCOMP-01-0124-FEDER-028417 and POCI-01-0145-FEDER-007440), and Centro 2020 Regional Operational Programme (CENTRO-01-0145-FEDER-000008: BrainHealth 2020). Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional “Una manera de hacer Europa” (PI16/00031, SAF2015-67643-P, RD16/0008/0026, and RD16/0008/0016) and by the Fundación Séneca, Agencia de Ciencia y Tecnología Región de Murcia (19881/GERM/15). | pt |
dc.language.iso | eng | pt |
dc.publisher | Springer Nature | pt |
dc.relation | PD/BD/ 114115/2015 | pt |
dc.relation | PD/BD/127821/2016 | pt |
dc.relation | PTDC/NEU-OSD/3123/2014 | pt |
dc.relation | UID/NEU/04539/2013 | pt |
dc.relation | BrainHealth 2020 - Detecção Precoce, Neuro-modulação e Terapias Avançadas para Neuropatologias | pt |
dc.relation | UID/NEU/04539/2019 | pt |
dc.relation | UIDB/04539/2020 | pt |
dc.relation | UIDP/04539/2020 | pt |
dc.relation | FCOMP-01-0124- FEDER-028417 | pt |
dc.relation | POCI-01-0145-FEDER-007440 | pt |
dc.rights | openAccess | pt |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | pt |
dc.title | Activation of adenosine A3 receptor protects retinal ganglion cells from degeneration induced by ocular hypertension | pt |
dc.type | article | - |
degois.publication.firstPage | 401 | pt |
degois.publication.issue | 5 | pt |
degois.publication.title | Cell Death & Disease | pt |
dc.relation.publisherversion | https://www.nature.com/articles/s41419-020-2593-y | pt |
dc.peerreviewed | yes | pt |
dc.identifier.doi | 10.1038/s41419-020-2593-y | pt |
degois.publication.volume | 11 | pt |
dc.date.embargo | 2020-05-21 | * |
uc.date.periodoEmbargo | 0 | pt |
item.fulltext | Com Texto completo | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.languageiso639-1 | en | - |
item.openairetype | article | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | open | - |
crisitem.project.grantno | CENTRO-01-0145-FEDER-000008 | - |
crisitem.project.grantno | CNC. IBILI | - |
crisitem.project.grantno | Center for Innovative Biomedicine and Biotechnology - CIBB | - |
crisitem.project.grantno | Center for Innovative Biomedicine and Biotechnology | - |
crisitem.author.researchunit | CNC - Center for Neuroscience and Cell Biology | - |
crisitem.author.orcid | 0000-0002-0477-1641 | - |
crisitem.author.orcid | 0000-0002-7541-7041 | - |
Appears in Collections: | I&D IBILI - Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
10.1038_s41419-020-2593-y.pdf | 2.45 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
8
checked on Nov 17, 2022
WEB OF SCIENCETM
Citations
20
12
checked on May 2, 2023
Page view(s)
285
checked on Oct 16, 2024
Download(s)
202
checked on Oct 16, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License